Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) EBIT per Share : $0.29 (TTM As of Dec. 2018)

View and export this data going back to 2014. Start your Free Trial

What is Parnell Pharmaceuticals Holdings EBIT per Share?

Parnell Pharmaceuticals Holdings's EBIT per Share for the six months ended in Dec. 2018 was $0.29. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2018 was $0.29.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Parnell Pharmaceuticals Holdings's EBIT per Share or its related term are showing as below:

PARNF's 3-Year EBIT Growth Rate is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 7.25
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Parnell Pharmaceuticals Holdings's EBIT for the six months ended in Dec. 2018 was $5.26 Mil.

Parnell Pharmaceuticals Holdings EBIT per Share Historical Data

The historical data trend for Parnell Pharmaceuticals Holdings's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Parnell Pharmaceuticals Holdings EBIT per Share Chart

Parnell Pharmaceuticals Holdings Annual Data

Trend

Jun12

Jun13

Jun14

Dec15

Dec16

Dec17

Dec18

EBIT per Share

Get a 7-Day Free Trial

-0.86

-0.68

-0.83

-0.59

0.29

Parnell Pharmaceuticals Holdings Semi-Annual Data
	Jun12	Jun13	Jun14	Dec15	Dec16	Dec17	Dec18
EBIT per Share	Get a 7-Day Free Trial			-0.86	-0.68	-0.83	-0.59	0.29

Parnell Pharmaceuticals Holdings EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Parnell Pharmaceuticals Holdings's EBIT per Share for the fiscal year that ended in Dec. 2018 is calculated as

	EBIT per Share		(A: Dec. 2018 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	5.256	/	18.027
=	0.29

Parnell Pharmaceuticals Holdings's EBIT per Share for the quarter that ended in Dec. 2018 is calculated as

	EBIT per Share		(Q: Dec. 2018 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	5.256	/	18.027
=	0.29

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2018 was $0.29

Parnell Pharmaceuticals Holdings (OTCPK:PARNF) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Parnell Pharmaceuticals Holdings EBIT per Share Related Terms

Thank you for viewing the detailed overview of Parnell Pharmaceuticals Holdings's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARNF) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

476 Gardeners Road, Unit 4, Century Estate, Alexandria, Sydney, NSW, AUS, 2015

Website

https://www.parnell.com

Parnell Pharmaceuticals Holdings Ltd is an Australia based veterinary pharmaceutical company. It is focused on developing, manufacturing and commercializing animal health solutions. The group manufactures and market products for companion animals and production animals. The firm also has a pipeline of drug products like Zydax, PAR121 and PAR122 and Luminous which covers therapeutic areas in orthopedics, dermatology, and nutraceuticals. The operating segments of the company are Companion animal, Production animal - U.S., Production animal - rest of world and Contract Manufacturing. It operates internationally and generates the majority of the revenue from the Production animal - U.S. segment which covers the group's reproductive hormone portfolio across production animal in the USA.